Mercedes Garayoa Berrueta-rekin lankidetzan egindako argitalpenak (27)

2021

  1. Bone marrow mesenchymal stromal cells in multiple myeloma: Their role as active contributors to myeloma progression

    Cancers, Vol. 13, Núm. 11

  2. Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma

    Cells, Vol. 10, Núm. 3

2020

  1. Filanesib for the treatment of multiple myeloma

    Expert Opinion on Investigational Drugs, Vol. 29, Núm. 1, pp. 5-14

  2. Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma

    Haematologica

  3. Protein translation inhibition is involved in the activity of the pan-pim kinase inhibitor pim447 in combination with pomalidomide-dexamethasone in multiple myeloma

    Cancers, Vol. 12, Núm. 10, pp. 1-20

2019

  1. Biological Background of Resistance to Current Standards of Care in Multiple Myeloma

    Cells, Vol. 8, Núm. 11

2017

  1. Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair

    Journal of Hematology and Oncology, Vol. 10, Núm. 1

  2. Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bor tezomib and dexamethasone

    Haematologica, Vol. 102, Núm. 1, pp. 168-175

  3. The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma

    Haematologica, Vol. 102, Núm. 12, pp. 2113-2124

  4. The novel pan-PIM kinase inhibitor, PIM447, displays dual antimyeloma and bone-protective effects, and potently synergizes with current standards of care

    Clinical Cancer Research, Vol. 23, Núm. 1, pp. 225-238

2015

  1. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone

    Leukemia, Vol. 29, Núm. 3, pp. 705-714

2014

  1. Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines

    PLoS ONE, Vol. 9, Núm. 3

  2. Preclinical activity of the oral proteasome inhibitor mln9708 in myeloma bone disease

    Clinical Cancer Research, Vol. 20, Núm. 6, pp. 1542-1554

  3. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: Implications in myeloma progression and myeloma bone disease

    Oncotarget, Vol. 5, Núm. 18, pp. 8284-8305

2013

  1. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile

    Blood, Vol. 122, Núm. 22, pp. 3591-3598

  2. RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications

    Investigational New Drugs, Vol. 31, Núm. 1, pp. 200-205

  3. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects

    Leukemia, Vol. 27, Núm. 2, pp. 430-440

2012

  1. CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype

    Haematologica, Vol. 97, Núm. 7, pp. 1110-1114

  2. Dasatinib as a bone-modifying agent: Anabolic and anti-resorptive effects

    PLoS ONE, Vol. 7, Núm. 4

  3. Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma

    Annals of Hematology, Vol. 91, Núm. 2, pp. 257-269